Navigation Links
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
Date:3/19/2012

BEDMINSTER, N.J., March 19, 2012 /PRNewswire/ -- Nautilus Neurosciences announced today that their Canadian promotional partner, Tribute Pharmaceuticals, a wholly owned subsidiary of Stellar Pharmaceuticals, was granted a Notice of Compliance (NOC) approval from Health Canada for CAMBIA® (diclofenac potassium for oral solution) in the treatment of acute migraine with or without aura in adults. CAMBIA® is expected to be launched in Canada during the second half of 2012. CAMBIA® has been available to patients in the United States since May 2010.

Nautilus Neurosciences has exclusive marketing rights for CAMBIA® in the United States and Canada, which they obtained from APR, a Swiss drug delivery and drug development company. Patents have been granted that protect the product in the United States through 2026.

"We congratulate our partners at Tribute Pharmaceuticals on the Health Canada approval and look forward to continuing to work with them on the Canadian launch of CAMBIA®. We are excited that CAMBIA® will be available as a treatment option for physicians and patients in Canada," said William Maichle, the CEO of Nautilus Neurosciences. Mr. Maichle highlighted, "With CAMBIA® now approved in both the United States and Canada, this marks another major milestone in the evolution of Nautilus to a best-in-class neurology-focused specialty pharmaceutical company."

Mr. Maichle added, "Looking forward, our strategy is to build an increasingly valuable company through the addition of complementary neurology-targeted therapies through in-licensing and acquisition opportunities. Mr. Maichle concluded, "[I] expect Nautilus Neurosciences to experience record growth in 2012 as CAMBIA® continues to fill an important unmet need for patients suffering from the debilitating effects of migraine."

About CAMBIA®

CAMBIA® (diclofenac potassium for oral solution) is the lead product from Nautilus Neurosciences and has been available for sale in the United States since May 2010. It is indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

CAMBIA® is a novel patented formulation of diclofenac potassium that is the only prescription-strength non-steroidal anti-inflammatory drug (NSAID) approved and indicated by the FDA for the acute treatment of migraine. Engineered using Dynamic Buffering Technology™, CAMBIA® is specifically designed for fast, effective relief from the symptoms of migraine. Working to treat the underlying pathophysiology of migraine, CAMBIA® has proven to be clinically effective in reducing migraine pain in as fast as 15 minutes.

About Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners.

For more information about Nautilus Neurosciences, please visit: www.nautilusneurosciences.com.

About Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products, with its primary focus on the Canadian market.

For further information on Stellar Pharmaceuticals, visit http://www.stellarpharma.com, and for information on its subsidiary, please visit http://www.tributepharma.com

About Applied Pharma Research

APR Applied Pharma Research SA is an independent, international, vertically integrated drug delivery and drug development company in healthcare, with registered offices in Switzerland and the United States. It is focused on the research and development of innovative and patented drug delivery systems as well as innovative pharmaceutical products primarily for oral and topical administration.

For more information about APR, please visit www.apr.ch  


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
2. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
3. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
4. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
5. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
7. Proteonomix Announces a Private Placement of $3.8 Million
8. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
9. ARUP Laboratories Announces Creation of Business Innovations Division
10. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
11. Regeneron Announces March 2012 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):